55757-60-3

Basic information

• Product Name: BOC-LYS(AC)-OH HCL
• Synonyms: BOC-L-LYSINE METHYL ESTER HYDROCHLORIDE;BOC-LYS-OME HCL;BOC-LYS(AC)-OH HCL;BOC-LYS-OM.HCL;Boc-Lys-OMe•N2-[(1,1-DIMETHYLETHOXY)CARBONYL]-L-LYSINE METHYL ESTER HCL;N-tert-Butoxycarbonyl-L-lysine methyl ester hydrochloride;boc-lys-omeCl
• CAS NO: 55757-60-3
• Molecular Formula: C₁₂H₂₄N₂O₄
• Molecular Weight: 296.79
• Product Categories: Lysine [Lys, K];Boc-Amino Acids and Derivative;Boc-Amino acid series
• Mol File: 55757-60-3.mol
• Article Data: 27

Chemical Properties

• Boiling Point: 404.4 °C at 760 mmHg
• Flash Point: 198.4 °C
• Appearance: /
• Density: 1.056g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.466
• Storage Temp.: Store at 0°C
• PKA: 11.16±0.46(Predicted)
• CAS DataBase Reference: BOC-LYS(AC)-OH HCL(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-LYS(AC)-OH HCL(55757-60-3)
• EPA Substance Registry System: BOC-LYS(AC)-OH HCL(55757-60-3)

Safety Data

• Hazardous Substances Data: 55757-60-3(Hazardous Substances Data)

Usage

Chemical Properties

Colorless to light yellow oil

Uses

Boc-L-Lysine Methyl Ester is a reagent in the synthesis of myxochelin analogs as antimetastatic agents.

InChI:InChI=1/C12H24N2O4/c1-12(2,3)18-11(16)14-9(10(15)17-4)7-5-6-8-13/h9H,5-8,13H2,1-4H3,(H,14,16)

Upstream product

• 55878-47-2 (R)-6-benzyloxycarbonylamino-2-tert-butoxycarbonylamino-hexanoic acid 
• 34404-32-5 (R)-2-amino-6-(((benzyloxy)carbonyl)amino)hexanoic acid 
• 923-27-3 D-lysine 
• 82611-49-2 methyl 6-N-benzyloxycarbonyl-2-N-BOC-D-lysinate 
• 106719-44-2 Boc-D-Lys-OH 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 13515-95-2 lysine methyl ester dihydrochloride 
• 13515-95-2 L-lysine methyl ester hydrochloride 
• 13734-28-6 Boc-Lys-OH 
• 136832-75-2 (S)-methyl 6-amino-2-((tert-butoxycarbonyl)amino)hexanoate acetate 
• 27894-50-4 methyl (2S)-2-amino-6-{[(benzyloxy)carbonyl]amino}hexanoate hydrochloride 
• 2389-45-9 Boc-Lys(Z)-OH 
• 108634-97-5 N^α-(tert-butoxycarbonyl)-N^ε-(tert-butyldimethylsilyloxycarbonyl)-L-lysine methyl ester 

Downstream Products

• 129483-55-2 (S)-2-tert-Butoxycarbonylamino-6-[3-(4-methyl-pyridin-3-yl)-propionylamino]-hexanoic acid methyl ester 
• 145385-47-3 N^ε-benzoyl-N^α-BOC-L-lysine methyl ester 
• 145385-46-2 N^ε-cinnamoyl-N^ε-(benzoyloxy)-N^α-BOC-L-lysine methyl ester 
• 1207187-98-1 tert-butyl (S)-1-(methoxycarbonyl)-5-(4-isopropoxy-6-methylpyrimidin-2-ylamino)pentylcarbamate 
• 1207187-97-0 tert-butyl (S)-1-(methoxycarbonyl)-5-(4-isopropoxy-pyrimidin-2-ylamino)pentylcarbamate 
• 1207187-99-2 tert-butyl (S)-1-(methoxycarbonyl)-5-(4-isopropoxy-6-phenylpyrimidin-2-ylamino)pentylcarbamate 
• 1224727-88-1 Boc-Lys(Boc-D-Orn(Boc))-OMe 
• 82835-03-8 N_α-t-butoxycarbonyl-N_ε-(2-cyanoethyl)-L-lysine methyl ester 
• 133546-18-6 2-tert-Butoxycarbonylamino-6-((8R,9S,13S,14S,17R)-3-hydroxy-13-methyl-16-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-ylamino)-hexanoic acid methyl ester 
• 129145-10-4 6-((R)-4-Benzyloxycarbonylamino-4-carbamoyl-butyrylamino)-2-tert-butoxycarbonylamino-hexanoic acid methyl ester 

Relevant articles and documents

PCSK9 ANTAGONIST COMPOUNDS

Disclosed are compounds of Formula (A), or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression

Hepatocyte growth factor (HGF), the ligand for the MET receptor tyrosine kinase, is a tumor-promoting factor that is abundant in the tumor microenvironment. Proteolytic activation of inactive pro-HGF by one or more of the serine endopeptidases matriptase, hepsin, and HGF activator is the rate-limiting step in HGF/MET signaling. Herein, we have rationally designed a novel class of side chain cyclized macrocyclic peptide inhibitors. The new series of cyclic tripeptides has superior metabolic stability and significantly improved pharmacokinetics in mice relative to the corresponding linear peptides. We identified the lead compound VD2173 that potently inhibits matriptase and hepsin, which was tested in parallel alongside the acyclic inhibitor ZFH7116 using both in vitro and in vivo models of lung cancer. We demonstrated that both compounds block pro-HGF activation, abrogate HGF-mediated wound healing, and overcome resistance to EGFR- and MET-targeted therapy in lung cancer models. Furthermore, VD2173 inhibited HGF-dependent growth of lung cancer tumors in mice.

Photoredox-Catalyzed Site-Selective α-C(sp3)?H Alkylation of Primary Amine Derivatives

The synthetic utility of tertiary amines to oxidatively generate α-amino radicals is well established, however, primary amines remain challenging because of competitive side reactions. This report describes the site-selective α-functionalization of primary amine derivatives through the generation of α-amino radical intermediates. Employing visible-light photoredox catalysis, primary sulfonamides are coupled with electron-deficient alkenes to efficiently and mildly construct C?C bonds. Interestingly, a divergence between intermolecular hydrogen-atom transfer (HAT) catalysis and intramolecular [1,5] HAT was observed through precise manipulation of the protecting group. This dichotomy was leveraged to achieve excellent α/δ site-selectivity.